Cancer risk evaluation in psoriasis: in search of the Holy Grail?
Benefit-risk assessment of systemic treatment in psoriasis is a dynamic process. Long-term safety of psoriasis therapies has been questioned, with the spectrum of systemic immunosuppression potentially leading to increased cancer risk. In this issue, Brauchli et al. report on a population-based analysis of cancer risk in a large cohort of psoriasis patients, most of whom had not been treated with systemic agents. The study prepares the ground for future prospective long-term cohort studies in psoriasis patients treated with systemic therapies, including biological agents.
Paul
Carle F
CF
Paul Sabatier University, Toulouse, France. paul.c@chu-toulouse.fr
Gourraud
Pierre-Antoine
PA
D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D009369:Neoplasms / Q000453:epidemiology* / Q000276:immunology*; D011565:Psoriasis / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D018570:Risk Assessment; D012307:Risk Factors
D007166:Immunosuppressive Agents